JP2022551290A - 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物 - Google Patents
芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物 Download PDFInfo
- Publication number
- JP2022551290A JP2022551290A JP2022520861A JP2022520861A JP2022551290A JP 2022551290 A JP2022551290 A JP 2022551290A JP 2022520861 A JP2022520861 A JP 2022520861A JP 2022520861 A JP2022520861 A JP 2022520861A JP 2022551290 A JP2022551290 A JP 2022551290A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- neurodegenerative diseases
- extract
- disease
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 89
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 59
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 229940079593 drug Drugs 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000001225 therapeutic effect Effects 0.000 title claims description 7
- 230000003449 preventive effect Effects 0.000 title description 2
- 239000012676 herbal extract Substances 0.000 claims abstract description 100
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 70
- 235000013305 food Nutrition 0.000 claims abstract description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 40
- 241000736199 Paeonia Species 0.000 claims description 31
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 31
- 208000018737 Parkinson disease Diseases 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 18
- 210000002569 neuron Anatomy 0.000 claims description 16
- 230000003542 behavioural effect Effects 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 230000004898 mitochondrial function Effects 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 8
- 230000030833 cell death Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 4
- 235000009120 camo Nutrition 0.000 claims description 4
- 235000005607 chanvre indien Nutrition 0.000 claims description 4
- 239000011487 hemp Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 230000009223 neuronal apoptosis Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 241000212314 Foeniculum Species 0.000 claims 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 39
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 33
- 238000012360 testing method Methods 0.000 description 31
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 27
- 229940080817 rotenone Drugs 0.000 description 27
- 239000013642 negative control Substances 0.000 description 22
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 241000411851 herbal medicine Species 0.000 description 13
- 239000007928 intraperitoneal injection Substances 0.000 description 13
- 238000000692 Student's t-test Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 238000012353 t test Methods 0.000 description 12
- 238000010171 animal model Methods 0.000 description 11
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 10
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000010825 rotarod performance test Methods 0.000 description 9
- 206010047700 Vomiting Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 230000008673 vomiting Effects 0.000 description 8
- 239000002131 composite material Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 230000001120 cytoprotective effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002025 microglial effect Effects 0.000 description 6
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 240000006927 Foeniculum vulgare Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012454 non-polar solvent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 210000003523 substantia nigra Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- NBAOBNBFGNQAEJ-UHFFFAOYSA-M tetramethylrhodamine ethyl ester perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 NBAOBNBFGNQAEJ-UHFFFAOYSA-M 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000218158 Clematis Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000007914 Labor Pain Diseases 0.000 description 2
- 208000035945 Labour pain Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241000208181 Pelargonium Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- -1 fluoroalkanes Chemical compound 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 241000601157 Clematis angustifolia Species 0.000 description 1
- 241000260447 Clematis armandii Species 0.000 description 1
- 241000915582 Clematis manshurica Species 0.000 description 1
- 241001078978 Clematis trichotoma Species 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 241001310717 Daphne genkwa Species 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000269849 Thunnus Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008916 wei-ling-xian Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
単一生薬抽出物の製造
洗浄して乾燥された芫花、威霊仙、天麻を用いた。それぞれ75gの芫花、威霊仙、天麻の生薬に10倍の70%(v/v)のエタノール水溶液を加えて常温で72時間にかけて撹拌させながら抽出し、抽出物を得た。その後、前記それぞれの抽出液をろ過して50~65℃で減圧濃縮してから、凍結乾燥して粉末状態の単一生薬抽出物を得た。
芫花、威霊仙及び天麻の複合生薬抽出物の製造
洗浄して乾燥された芫花、威霊仙、天麻の生薬を1:1:1の重量比で合計75gとなるように混合した後、10倍の70%(v/v)のエタノール水溶液を加えて常温で72時間にかけてよく撹拌させながら抽出した。その後、前記抽出液をろ過して50~65℃で減圧濃縮してから、凍結乾燥して粉末状態の複合生薬抽出物(混合抽出物)を得た。
威霊仙及び天麻の複合生薬抽出物の製造
洗浄して乾燥された威霊仙及び天麻生薬を1:1の重量比で合計80gとなるように混合した後、10倍の70%(v/v)のエタノール水溶液を加えて常温で72時間にかけてよく撹拌させながら抽出した。その後、前記抽出液をろ過して50~65℃で減圧濃縮してから、凍結乾燥して粉末状態の複合生薬抽出物(混合抽出物)を得た。
芫花、威霊仙及び天麻の複合生薬抽出物の製造
洗浄して乾燥された芫花、威霊仙、天麻を利用して次のように複合生薬抽出物を製造し、実施例9~11の実験に用いた。芫花の場合、円形に、威霊仙と天麻の場合、粗切(4,750μm)のふるいを通過する大きさに粉砕した後、実験に用いた。前記芫花、威霊仙、天麻を表1に記載された重量比(w/w)に応じて混合した後、10倍の70%(v/v)のエタノール水溶液を加えて常温で72時間にかけて抽出した。抽出液をろ過した後、50~65℃で減圧濃縮してから、凍結乾燥して粉末状態の複合生薬抽出物を得た。
Rotenone-誘発パーキンソン病動物モデルに対する複合生薬抽出物の運動能力の改善効能
Rotenoneは殺虫剤として用いられる物質であり、ミトコンドリアの電子伝達系を阻害することでミトコンドリアの活性を抑制させるが、その場合、脳細胞が死滅し、結局、運動機能が低下する。従って、複合生薬抽出物の行動能力を向上させる効能を検証するためにRotenoneによって誘発されたパーキンソン病動物モデルにおいて運動機能性を確認できる実験を行った。
(1)正常群(n=8)
(2)Rotenone(陰性対照群;Sigma-Aldrich、St. Louis、MO、USA)(n=8;1mg/kg/日の濃度でRotenoneの腹腔内注射)
(3)芫花、威霊仙及び天麻の複合生薬抽出物(1:1:1の比率)1、3、10mg/kg(n=8;抽出物の経口投与、Rotenoneの腹腔内注射)
(4)芫花抽出物1、3mg/kg(n=8;抽出物の経口投与、Rotenoneの腹腔内注射)
(5)威霊仙抽出物1、3mg/kg(n=8;抽出物の経口投与、Rotenoneの腹腔内注射)
(6)天麻抽出物1、3mg/kg(n=8;抽出物の経口投与、Rotenoneの腹腔内注射)
(7)L-DOPA 25mg/kg(陽性対照群;Sigma-Aldrich、USA)(n=8;L-DOPAの腹腔内注射、Rotenoneの腹腔内注射)
ドーパミン性神経細胞株における複合生薬抽出物のMPP+による細胞毒性の保護効能
本実施例においては、複合生薬抽出物の細胞保護活性を評価した。芫花、威霊仙及び天麻の複合生薬抽出物のMPP+を処理した神経細胞損傷を保護する効果有無を確認するために、SH-SY5Y細胞株を利用してWST-1 assayを行った。
ドーパミン性神経細胞株における複合生薬抽出物のMPP+による活性酸素種生成の減少効能
本実施例においては、SH-SY5Y神経細胞毒素物質であるMPP+を処理した場合、芫花、威霊仙及び天麻の複合生薬抽出物の活性酸素種(ROS)の減少能を確認した。活性酸素種によって細胞の中でDCFに転換されて緑色蛍光を発するDCF-DA(2’,7’-dichlorodihydrofluorescein diacetate、Sigma-Aldrich、USA)を利用して前記の実施例2において培養したSH-SY5Y細胞内の活性酸素種の水準を測定した。
ドーパミン性神経細胞株における複合生薬抽出物のMPP+によるミトコンドリア機能損傷の改善効能
本実施例においては、SH-SY5Y神経細胞の毒素物質であるMPP+を処理した場合、芫花、威霊仙及び天麻の複合生薬抽出物のミトコンドリアの機能を保護する効果を分析した。正常ミトコンドリアの細胞内へ吸収されて蛍光を発するTMRE(Tetramethylrhodamine、Ethyl Ester、Perchlorate、Sigma-Aldrich、87917)を利用して蛍光水準を測定することでミトコンドリアの機能を分析した。
ドーパミン性神経細胞株における複合生薬抽出物のMPP+による細胞死滅の減少効能
本実施例においては、SH-SY5Y神経細胞の毒素物質であるMPP+を処理した場合、芫花、威霊仙及び天麻の複合生薬抽出物の細胞内アポトーシスの減少能の効果を分析した。
ミクログリア細胞株における複合生薬抽出物のLPSによる炎症反応の抑制効能
芫花、威霊仙及び天麻の複合生薬抽出物の抗炎症効能を確認するために、Griess assayを利用してマウスミクログリア細胞であるBV2細胞内の酸化窒素(NO)の含量の変化を測定した。
Rotenone-誘発パーキンソン病動物モデルに対する複合生薬抽出物の運動能力の改善効能
体重20~22gの5週齢の雄C57BL/6マウス(Orient Bio Inc.、Republic of Korea)を利用した。動物はNIH(NIH publication No.85-23、revised 1985)のガイドラインに従って12時間の昼、12時間の夜のサイクルの条件下で23±1℃の室内温度で維持した。マウスを以下のようにランダムに5つのグループに分けて生体内実験を行った。
(1)正常群(n=8)
(2)Rotenone(陰性対照群;Sigma-Aldrich、St.Louis、MO、USA)(n=8;1mg/kg/日の濃度でRotenoneの腹腔内注射)
(3)芫花、威霊仙及び天麻の複合生薬抽出物(1:1:1の比率)5mg/kg(n=8;抽出物の経口投与、Rotenoneの腹腔内注射)
(4)威霊仙及び天麻の複合生薬抽出物(1:1の比率)5mg/kg(n=8;抽出物の経口投与、Rotenoneの腹腔内注射)
(5)L-DOPA 25mg/kg(陽性対照群;Sigma-Aldrich、USA)(n=8;L-DOPAの腹腔内注射、Rotenoneの腹腔内注射)
ミクログリア細胞株における複合生薬抽出物のLPSによる炎症反応の抑制効能
芫花、威霊仙及び天麻の複合生薬抽出物及び威霊仙及び天麻の複合生薬抽出物の抗炎症効能を確認するために、Griess assayを利用してマウスミクログリア細胞であるBV2細胞内の酸化窒素(NO)の含量の変化を測定した。
配合比率別の複合生薬抽出物のビーグル犬での嘔吐発生有無の比較
本実施例においては、芫花、威霊仙及び天麻の1:1:1、1:5:5または1:10:10の配合比率による複合生薬抽出物を経口投与後のビーグル犬での体重変化及び嘔吐などの一般症状の変化を観察した。
配合比率別の複合生薬抽出物のMPP+または6-ヒドロキシドーパミンによる細胞毒性保護効能の比較
芫花、威霊仙及び配合比率別の複合生薬抽出物がMPP+または6-ヒドロキシドーパミン(6-hydroxydopamine、6-OHDA)柔道の神経細胞損傷を保護する効果有無を確認するために、SH-SY5Y細胞株を利用してMTT assayを行った。
MPTP柔道パーキンソン病動物モデルに対する複合生薬抽出物の運動能力の改善効能
MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)は、ミトコンドリアの電子伝達系を阻害することでミトコンドリアの活性を抑制させるが、その場合、脳細胞が死滅し、結局、運動機能が低下する。従って、複合生薬抽出物の行動能力を向上させる効能を検証するためにMPTPによって誘発されたパーキンソン病動物モデルにおいて運動機能性を確認できる実験を行った。
(1)正常群(n=8)
(2)MPTP(陰性対照群;Sigma-Aldrich、St. Louis、MO、USA)(n=8;30mg/kg/日の濃度で1日1回5日間、腹腔内投与)
(3)MPTP+芫花、威霊仙及び天麻の1:5:5の複合生薬抽出物(製造例4-2)30mg/kg(n=8;1日1回12日間、抽出物の経口投与、MPTPの腹腔内投与)
(4)MPTP+芫花、威霊仙及び天麻の1:10:10複合生薬抽出物(製造例4-3)30mg/kg(n=8;1日1回12日間、抽出物の経口投与、MPTPの腹腔内投与)
Claims (21)
- 芫花(ゲンカ)、威霊仙(イレイセン)、及び天麻(テンマ)からなる群より選ばれる少なくとも二つの生薬抽出物を含む、神経変性疾患の予防または治療用薬学組成物。
- 前記生薬抽出物が、芫花、威霊仙、及び天麻からなる群より選ばれる生薬から抽出されたそれぞれの抽出物を含むか、あるいは芫花、威霊仙、及び天麻からなる群より選ばれる生薬の混合物から抽出されたことを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記生薬抽出物が、水、C1~C6のアルコール、酢酸、及びそれらの混合溶媒からなる群より選ばれる溶媒で抽出されたことを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記生薬抽出物が、0.01~90%のエタノール抽出物であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記生薬抽出物が、50~70%のエタノール抽出物であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記神経変性疾患が、パーキンソン病、アルツハイマー病、ピック病、ハンチントン病、ルーゲーリッグ病、プリオン病、レビー小体型認知症、多系統萎縮症、進行性核上性麻痺、フリードライヒ運動失調症、側頭葉てんかん、及び脳卒中からなる群より選ばれた少なくとも一つであることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記神経変性疾患がパーキンソン病であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、芫花及び威霊仙の生薬抽出物を含み、芫花及び威霊仙の配合重量比が1:1~20であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、芫花及び天麻の生薬抽出物を含み、芫花及び天麻の配合重量比が1:1~20であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、威霊仙及び天麻の生薬抽出物を含み、威霊仙及び天麻の配合重量比が1:0.05~20であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、芫花、威霊仙、及び天麻の生薬抽出物を含み、芫花、威霊仙、及び天麻の配合重量比が1:1~20:1~20であることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 芫花、威霊仙、及び天麻の配合重量比が1:5~15:5~15であることを特徴とする、請求項11に記載の神経変性疾患の予防または治療用薬学組成物。
- 芫花、威霊仙、及び天麻の配合重量比が1:10:10であることを特徴とする、請求項11に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、行動能力を向上させることを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、神経細胞において毒性による細胞死滅を抑制することを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、神経細胞において活性酸素種(ROS)の生成を抑制することを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、神経細胞においてミトコンドリアの機能を保護することを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、神経細胞のアポトーシスを抑制することを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 前記薬学組成物が、酸化窒素(NO)の生成を抑制することを特徴とする、請求項1に記載の神経変性疾患の予防または治療用薬学組成物。
- 芫花、威霊仙、及び天麻からなる群より選ばれる少なくとも二つの生薬抽出物を含む、神経変性疾患の予防または改善用食品組成物。
- 芫花、威霊仙、及び天麻からなる群より選ばれる少なくとも二つの生薬抽出物を含む、神経変性疾患の予防または改善用飼料組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0125714 | 2019-10-10 | ||
KR20190125714 | 2019-10-10 | ||
PCT/KR2020/013812 WO2021071321A1 (ko) | 2019-10-10 | 2020-10-08 | 원화, 위령선, 및 천마의 복합 생약 추출물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022551290A true JP2022551290A (ja) | 2022-12-08 |
JP7361903B2 JP7361903B2 (ja) | 2023-10-16 |
Family
ID=75437379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022520861A Active JP7361903B2 (ja) | 2019-10-10 | 2020-10-08 | 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230263852A1 (ja) |
EP (1) | EP4043024A4 (ja) |
JP (1) | JP7361903B2 (ja) |
KR (1) | KR102310764B1 (ja) |
CN (1) | CN114929253A (ja) |
CA (1) | CA3153252A1 (ja) |
WO (1) | WO2021071321A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110138531A (ko) * | 2010-06-21 | 2011-12-28 | 건국대학교 산학협력단 | 신경 세포사 억제 활성을 갖는 천마 추출물을 포함하는 뇌질환의 예방 및 치료용 약학 조성물 |
KR20160058992A (ko) * | 2014-11-11 | 2016-05-26 | 강원대학교산학협력단 | 위령선 추출물을 함유하는 치매 예방 또는 치료 또는 인지능 개선용 조성물 |
KR101859196B1 (ko) * | 2016-11-14 | 2018-05-17 | 한국생명공학연구원 | 팥꽃나무 꽃 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경퇴행성 질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101166481B1 (ko) | 2010-05-14 | 2012-07-19 | 경희대학교 산학협력단 | 목단피 추출물을 함유하는 파킨슨병 예방 및 치료용 조성물 |
KR101436017B1 (ko) | 2011-01-26 | 2014-08-29 | 경희대학교 산학협력단 | 백렴 추출물을 유효성분으로 함유하는 치매 또는 파킨슨병 예방 및 치료용 조성물 |
CN109568499A (zh) * | 2011-03-29 | 2019-04-05 | 百疗医株式会社 | 神经疾病的治疗及记忆力减退改善用生药组合物 |
CN102335348A (zh) * | 2011-10-09 | 2012-02-01 | 北京科莱博医药开发有限责任公司 | 一种用于防治帕金森氏病的天麻植物提取物及其制备方法 |
CN103432426B (zh) * | 2013-09-13 | 2015-01-07 | 郎晓玲 | 一种治疗神经性肌肉萎缩的中药片剂及其制备方法 |
CN104547897A (zh) * | 2014-12-09 | 2015-04-29 | 张祺 | 一种治疗帕金森病的中药组合物 |
-
2020
- 2020-10-08 CN CN202080070492.5A patent/CN114929253A/zh active Pending
- 2020-10-08 EP EP20873461.6A patent/EP4043024A4/en active Pending
- 2020-10-08 WO PCT/KR2020/013812 patent/WO2021071321A1/ko unknown
- 2020-10-08 KR KR1020200130585A patent/KR102310764B1/ko active IP Right Grant
- 2020-10-08 JP JP2022520861A patent/JP7361903B2/ja active Active
- 2020-10-08 CA CA3153252A patent/CA3153252A1/en active Pending
- 2020-10-08 US US17/767,604 patent/US20230263852A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110138531A (ko) * | 2010-06-21 | 2011-12-28 | 건국대학교 산학협력단 | 신경 세포사 억제 활성을 갖는 천마 추출물을 포함하는 뇌질환의 예방 및 치료용 약학 조성물 |
KR20160058992A (ko) * | 2014-11-11 | 2016-05-26 | 강원대학교산학협력단 | 위령선 추출물을 함유하는 치매 예방 또는 치료 또는 인지능 개선용 조성물 |
KR101859196B1 (ko) * | 2016-11-14 | 2018-05-17 | 한국생명공학연구원 | 팥꽃나무 꽃 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경퇴행성 질환 예방 또는 치료용 약학 조성물 |
Non-Patent Citations (2)
Title |
---|
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. Vol.2013, Article ID:514095, JPN6023017092, 2013, pages 1 - 13, ISSN: 0005049061 * |
JOURNAL OF NATURAL PRODUCTS, vol. 79, JPN6023017093, 2016, pages 1604 - 1609, ISSN: 0005049060 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210042837A (ko) | 2021-04-20 |
JP7361903B2 (ja) | 2023-10-16 |
CA3153252A1 (en) | 2021-04-15 |
CN114929253A (zh) | 2022-08-19 |
WO2021071321A1 (ko) | 2021-04-15 |
EP4043024A4 (en) | 2023-10-18 |
US20230263852A1 (en) | 2023-08-24 |
KR102310764B1 (ko) | 2021-10-08 |
EP4043024A1 (en) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2697670C9 (ru) | Фармацевтическая композиция, содержащая силибин и экстракт корня пуэрарии | |
KR102083661B1 (ko) | 밀크씨슬, 강황, 감초 및 결명자를 포함하는 숙취 해소용 조성물 | |
JP2023538664A (ja) | ジンセノサイドRg3およびジンセノサイドRg5の組成物ならびに抗腫瘍効果を含むその医薬用途 | |
AU2006209110B2 (en) | Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts | |
KR101794006B1 (ko) | 식물 추출물을 포함하는 염증 개선용 조성물 | |
KR20150033797A (ko) | 아토피성 피부질환 예방 및 치료용 약학적 조성물 | |
WO2016117705A1 (ja) | 肝細胞増殖因子産出誘導剤 | |
CN107648330B (zh) | 一种基于黑种草的降血糖组合物以及降血糖蒙药 | |
JP2001226280A (ja) | 黄色ブドウ球菌エンテロトキシン産生抑制剤 | |
KR20130040579A (ko) | 생약 추출물을 포함하는 신장암 예방 또는 치료용 약학적 조성물 | |
Arunabha et al. | Trigonella foenum-graecum: A review on its traditional uses, phytochemistry and pharmacology | |
JP7361903B2 (ja) | 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物 | |
WO2018172436A1 (fr) | Formulations comprenant des actifs issus de la plante murraya koenigii | |
KR101060909B1 (ko) | 뇌 신경 세포 보호물질을 포함하는 질경이 추출물을포함하는 조성물 | |
RU2311917C2 (ru) | Композиция для лечения и профилактики онкологических заболеваний | |
CN107050177A (zh) | 一种用于治疗痤疮的中药组合物及其制备方法 | |
EP2793917B1 (de) | Extrakt aus rhus copallina zur verwendung als arzneimittel | |
WO2011042469A1 (de) | Verwendung einer zusammensetzung auf basis von eremophilanoliden | |
JP4105498B2 (ja) | アトピー性疾患の症状の予防・緩和に有効な組成物 | |
TW201306851A (zh) | 用於治療糖尿病之植物萃取物及其製備方法 | |
CN101816708B (zh) | 治疗风湿病的中药组合物及其制备方法 | |
KR20040008975A (ko) | 뇌기능 및 인지 기능 개선 활성을 갖는 조성물 | |
CN112057535B (zh) | 一种预防或/和治疗血脂异常的中药组合物的制备方法 | |
CN112057536B (zh) | 一种预防或/和治疗血脂异常的中药组合物及其应用 | |
RATHOUR et al. | Review on Syzygium cumini Linn: A promising ethnopharmacological plant. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230904 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231003 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7361903 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |